glp-1 agonists and pancreatitis New data links for weight loss with higher risk for pancreatitis, GI events glp 1 agonist side effects
Description
These are not optional add-ons
This has led to renewed interest in understanding the safety of GIP/GIPR in humans
Holst JJ, Orskov C
While the recent phase 3 trial for orforglipron was specifically for type 2 diabetes and not weight loss, the study found that patients who took the drug lost considerable weight
